Chemical libraries: How dark is HTS dark matter?
Explore this paper's citation graph
Summary
An in-depth exploration of the bioactivity of this 'dark matter' does in fact reveal some compounds of interest.
- Type
- letter
- Published
- 2015-12-01
- Cited by
- 11
- References
- 5
- OpenAlex
- https://openalex.org/W1783550095
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:205303227
Keywords
Dark matter, Physics, Astronomy
References
- Estimation of the size of drug-like chemical space based on GDB-17 data
- Rapid Selection of Cyclic Peptides that Reduce α-Synuclein Toxicity in Yeast and Animal Models
- New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays.
- The influence of drug-like concepts on decision-making in medicinal chemistry
- Rational Methods for the Selection of Diverse Screening Compounds
Cited by
- Natural Products as Sources of New Drugs from 1981 to 2014.
- Filtering promiscuous compounds in early drug discovery: is it a good idea?
- Drugs as habitable planets in the space of dark chemical matter.
- Molecular Connectivity Predefines Polypharmacology: Aliphatic Rings, Chirality, and sp3 Centers Enhance Target Selectivity
- Predicted Biological Activity of Purchasable Chemical Space
- Identification of Metabolites Identical and Similar to Drugs as Candidates for Metabolic Engineering.
- Docking finds GPCR ligands in dark chemical matter.
- Creating and screening natural product libraries
- “Molecular Anatomy”: a new multi-dimensional hierarchical scaffold analysis tool
- “Molecular Anatomy”: A New Multi-Dimensional Hierarchical Scaffold Analysis tool
- “Molecular Anatomy”: A New Multi-Dimensional Hierarchical Scaffold Analysis tool
- Additional file 1 of “Molecular Anatomy”: a new multi-dimensional hierarchical scaffold analysis tool
- Combinatorial Chemistry Online Volume 18, Issue 2, February 2016
- Survival of the Fittest Computational Chemists, Computers, and Reference Works (Over a 30-Year Period)
- Computational Drug Design Methods—Current and Future Perspectives